Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for CVS Health (NYSE:CVS) from Market ...

Leerink analyst Jonathan Chang upgraded Genmab (GMAB) to Outperform from Market Perform with a $27 price target, citing a longer-term view ...

“We see the reward as positively skewed on a risk-adjusted basis,” analysts at Leerink Partners wrote, citing improving ...

Leerink analyst Michael Cherny upgraded CVS Health (CVS) to Outperform from Market Perform with a price target of $75, up from $55. The firm ...

Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Axsome Therapeutics in a research report issued ...

Investment analysts at Leerink Partnrs reduced their FY2028 earnings per share estimates for shares of Inspire Medical Systems in a report released on Tuesday, February 11th. Leerink Partnrs analyst M ...

Leerink Partners analyst shifted the rating for Genmab A/S (NASDAQ:GMAB) stock from Market Perform to Outperform, maintaining a price target (PT) of $27.00. The upgrade reflects a positive long-term ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

Leerink Partners heeft dinsdag een kleine aanpassing gedaan aan het koersdoel van Inspire Medical Systems (NYSE: INSP ), met een verhoging van $193,00 naar $194,00, terwijl het Market Perform advies v ...

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied ...